Sobi Licenses Lacutamab for T-Cell Lymphoma in $75M Upfront Deal with Innate Pharma — Swedish Orphan Biovitrum AB (Sobi)

Event summary

Sobi partners with Innate Pharma to license lacutamab for cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides.
$75M upfront payment, with potential $40M in near-term milestones and up to $465M in future regulatory/commercial milestones.
TELLOMAK-3 Phase 3 trial initiation enabled; Sobi gains exclusive global commercialization rights upon accelerated approval.
Lacutamab has received Fast Track, PRIME, Orphan Drug, and Breakthrough Therapy designations for CTCL indications.

The big picture

This deal underscores Sobi’s strategy of bolstering its rare disease portfolio through targeted partnerships, while Innate Pharma gains a commercialization partner with global scale. The $75M upfront payment highlights the strategic value of lacutamab, which addresses high-unmet needs in CTCL subtypes. Success hinges on regulatory milestones and Sobi’s ability to execute in a competitive oncology landscape.

What we're watching

Regulatory Momentum: Whether the TELLOMAK-3 trial delivers data sufficient for accelerated approval in Sézary syndrome and full approvals in key jurisdictions.
Commercialization Strategy: How Sobi leverages its rare disease expertise to globalize lacutamab's reach post-approval.
Financial Upside: The pace at which Innate Pharma realizes milestone and royalty payments as development progresses.